Jen­nifer Zi­olkows­ki re­signs from CFO post at Sol­id Bio­sciences; Sean Bo­hen's Ole­ma On­col­o­gy adds San­dra Horn­ing to board of di­rec­tors

→ Jen­nifer Zi­olkows­ki has de­cid­ed to step down from Ilan Gan­ot’s team at Sol­id Bio­sciences “to pur­sue a new ca­reer op­por­tu­ni­ty,” ac­cord­ing to an SEC doc­u­ment filed Fri­day. Zi­olkows­ki will con­tin­ue to be Sol­id’s CFO un­til Jan. 29, 2021. The day af­ter she an­nounced her res­ig­na­tion at the com­pa­ny, the Duchenne mus­cu­lar dy­s­tro­phy biotech en­tered in­to a con­sult­ing agree­ment with Dan­forth Ad­vi­sors, at which point Dan­forth man­ag­ing part­ner Stephen Di­Pal­ma was named in­ter­im CFO. Di­Pal­ma has been a CFO be­fore at Fo­rum Phar­ma­ceu­ti­cals and Aquila Bio­phar­ma­ceu­ti­cals, and he found­ed Cat­a­lyst On­col­o­gy and Athena Di­ag­nos­tics.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER